HIF1A and colitis: Recent studies have shown that regulating glycolysis and M1 polarization facilitate the recovery from colitis by inhibiting the mTORC1/HIF-1α signaling pathway; this therapeutic effect can be counteracted by the mTORC1 agonist, l-leucine (82).